Quarterly ResultMay 7, 2026, 08:52 AM
argenx Q1 Product Sales $1.3B, Up 63%; Operating Profit +183%
AI Summary
argenx SE reported strong first-quarter 2026 financial results, with global product net sales increasing 63% year-over-year to $1.3 billion and operating profit surging 183% to $394 million. The company also provided a positive business update, highlighting the upcoming PDUFA decision for seronegative gMG on May 10, 2026, and several pipeline advancements. Key leadership changes included Karen Massey's appointment as CEO and Tim Van Hauwermeiren as Chairperson of the Board.
Key Highlights
- Global product net sales reached $1.3 billion in Q1 2026, a 63% year-over-year increase.
- Operating profit grew 183% year-over-year to $394 million in Q1 2026.
- Profit for the period increased 116% year-over-year to $366 million.
- Basic profit per share was $5.90, up from $2.78 in Q1 2025.
- Cash, cash equivalents, and current financial assets totaled $4.9 billion as of March 31, 2026.
- PDUFA target action date for seronegative gMG is May 10, 2026.
- Topline results for the ALKIVIA study (myositis) are expected in Q3 2026.
- Karen Massey was appointed Chief Executive Officer, and Tim Van Hauwermeiren became Chairperson of the Board.